For the year ending 2025-12-31.
| Income Statement | 2025-12-31 | |||
|---|---|---|---|---|
| General and administrative | 2,967,812 | |||
| Total operating expenses | 2,967,812 | |||
| Loss from operations | -2,967,812 | |||
| Interest expense, related parties | 215,903 | |||
| Interest income | 76,589 | |||
| Forgiveness of unrelated vendor payables | 2,142,297 | |||
| Change in fair value of deferred underwriting fee - paid in common stock | -196,000 | |||
| Change in the fair value of warrant liability | -54,312 | |||
| Loss on exchange of common stock for warrants | -1,740,000 | |||
| Fair value of common stock to be issued for contingent liability | 7,360,000 | |||
| Total other expense, net | -7,238,705 | |||
| Net loss | -10,206,517 | |||
| Basic EPS | -0.43 | |||
| Diluted EPS | -0.43 | |||
| Basic Average Shares | 23,753,561 | |||
| Diluted Average Shares | 23,753,561 | |||
Liminatus Pharma, Inc. (LIMN)
Liminatus Pharma, Inc. (LIMN)